{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T04:25:26Z","timestamp":1774671926819,"version":"3.50.1"},"reference-count":73,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.2217\/14622416.6.5.491","type":"journal-article","created":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T11:07:22Z","timestamp":1133435242000},"page":"491-501","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacogenomics and Functional Gastrointestinal Disorders"],"prefix":"10.1080","volume":"6","author":[{"given":"Michael","family":"Camilleri","sequence":"first","affiliation":[{"name":"Mayo Clinic College of Medicine, Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Gastroenterology Research Unit, Charlton 8\u2013110200 First Street S.W., Rochester, MN55905, USA Tel:"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2005,11,24]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.37095"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.21908"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.4065\/75.9.907"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.440_j.x"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.27995"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.12.1703"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"crossref","unstructured":"Camilleri M : Is there a SERT-ain association with IBS? Gut 53 1396\u20131399 (2004).","DOI":"10.1136\/gut.2004.039826"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.030882"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.01.006"},{"key":"e_1_3_2_3_10_1","volume-title":"The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment: A Multinational Consensus.","author":"Drossman DA","year":"2000","unstructured":"Drossman DA , CorazziariE, TalleyNJ, ThompsonWG, WhiteheadWE (Eds): The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment: A Multinational Consensus. Degnon Associates, McLean, VA, USA (2000)."},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2008.ii43"},{"key":"e_1_3_2_3_12_1","volume-title":"Gastroenterol. Clin. North Am.: Irritable Bowel Syndrome.","author":"Park M","unstructured":"Park M -I, Camilleri M: Genetics and genotypes in IBS: implications for diagnosis and treatment. In: Gastroenterol. Clin. North Am.: Irritable Bowel Syndrome. Talley NJ (Ed.), Elsevier Publishers, Philadelphia, PA, USA, 34(2), 305\u2013317 (2005)."},{"key":"e_1_3_2_3_13_1","article-title":"The genetics of irritable bowel syndrome.","author":"Saito YA","unstructured":"Saito YA , LockeGR, TalleyNJ: The genetics of irritable bowel syndrome.Clin. Gastroenterol. Hepatol. (In press).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.09.006"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(01)80255-9"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00454-9"},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01537277"},{"key":"e_1_3_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01303162"},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"crossref","unstructured":"Creed F FernandesL GuthrieE et al.: North of England IBS Research Group: The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology124 303\u2013317 (2003).","DOI":"10.1053\/gast.2003.50055"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.35.4.536"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90008-6"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.46.4.474"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00375.x"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.35990"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2982.2003.00389.x"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.14.2.185"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70203-3"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2982.2002.00328.x"},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01449.x"},{"key":"e_1_3_2_3_30_1","author":"Evans BW","unstructured":"Evans BW , ClarkWK, MooreDJ, Whorwell\u00a0PJ: Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. (1), CD003960 (2004).","journal-title":"Cochrane Database Syst Rev. (1), CD003960 (2004)."},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00356-8"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.286.5439.487"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00669-3"},{"key":"e_1_3_2_3_34_1","article-title":"Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly.","volume":"42","author":"Shulman RW","year":"1997","unstructured":"Shulman RW , OzdemirV: Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly.Can. J. Psychiatr.42(Suppl. 1), 4S\u20139S (1997).","journal-title":"Can. J. Psychiatr."},{"key":"e_1_3_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.17.2.102"},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/331442a0"},{"key":"e_1_3_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.141"},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1139\/y82-001"},{"key":"e_1_3_2_3_39_1","first-page":"126","article-title":"Pharmacogenetics of desipramine metabolism.","volume":"32","author":"Musa MN","year":"1994","unstructured":"Musa MN , MiesckeKJ: Pharmacogenetics of desipramine metabolism.Int. J. Clin. Pharmacol. Ther.32, 126\u2013130 (1994).","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"e_1_3_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200405000-00002"},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200010000-00002"},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe048278"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443140-00003"},{"key":"e_1_3_2_3_44_1","volume":"128","author":"Gonenne J","year":"2005","unstructured":"Gonenne J , FerberI, BurtonD et al.: Effect of a peripheral mu-opioid antagonist, alvimopan on gastrointestinal transit in health: reversal of codeine effects and stimulation of colon transit. Gastroenterology128, A94 (2005).","journal-title":"Gastroenterology"},{"key":"e_1_3_2_3_45_1","first-page":"441","volume":"278","author":"Aklillu E","year":"1996","unstructured":"Aklillu E , PerssonI, BertilssonL, Johansson\u00a0I, Rodrigues F, Ingelman-Sundberg M: Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther.278, 441\u2013446 (1996).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90040-6"},{"key":"e_1_3_2_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00225-X"},{"key":"e_1_3_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200501203520317"},{"key":"e_1_3_2_3_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199606000-00007"},{"key":"e_1_3_2_3_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.41081.x"},{"key":"e_1_3_2_3_51_1","author":"Camilleri CE","unstructured":"Camilleri CE , CarlsonPJ, CamilleriM et\u00a0al.: A study of candidate genotypes associated with dyspepsia in a USA community. Am. J. Gastroenterol. (In press).","journal-title":"Am. J. Gastroenterol"},{"key":"e_1_3_2_3_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05841.x"},{"key":"e_1_3_2_3_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.035451"},{"key":"e_1_3_2_3_54_1","first-page":"18","article-title":"Serotonin transporter gene polymorphism in healthy adults and patients with irritable bowel syndrome.","volume":"43","author":"Lee DY","year":"2004","unstructured":"Lee DY , ParkHJ, KimWH, LeeSI, SeoYJ, ChoiYC: Serotonin transporter gene polymorphism in healthy adults and patients with irritable bowel syndrome.Korean J. Gastroenterol.43, 18\u201322 (2004).","journal-title":"Korean J. Gastroenterol."},{"key":"e_1_3_2_3_55_1","doi-asserted-by":"crossref","unstructured":"Gonsalkorale WM PerreyC PravicaV WhorwellPJ HutchinsonIV: Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 52 91\u201393 (2003).","DOI":"10.1136\/gut.52.1.91"},{"key":"e_1_3_2_3_56_1","article-title":"Tumor necrosis factor \u03b1 and interleukin 10 gene polymorphisms in irritable bowel syndrome.","volume":"126","author":"Veek P","year":"2004","unstructured":"Veek P , KroonY, BergM, VerspagetH, MascleeA: Tumor necrosis factor \u03b1 and interleukin 10 gene polymorphisms in irritable bowel syndrome.Gastroenterology126, A52 (2004).","journal-title":"Gastroenterology"},{"key":"e_1_3_2_3_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023160"},{"key":"e_1_3_2_3_58_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.34780"},{"key":"e_1_3_2_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)80396-7"},{"key":"e_1_3_2_3_60_1","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-178-42016"},{"key":"e_1_3_2_3_61_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00002.x-i2"},{"key":"e_1_3_2_3_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.03177.x"},{"key":"e_1_3_2_3_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.35.4.536"},{"key":"e_1_3_2_3_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199805000-00011"},{"key":"e_1_3_2_3_65_1","first-page":"297","volume":"92","author":"Choi M","year":"1997","unstructured":"Choi M -G, Camilleri M, O\u2019Brien MD, Kammer PP, Hanson RB: A pilot study of motility and tone of the left colon in diarrhea due to functional disorders and dysautonomia. Am. J. Gastroenterol.92, 297\u2013302 (1997).","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_3_2_3_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(02)00267-X"},{"key":"e_1_3_2_3_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-4388(00)00088-X"},{"key":"e_1_3_2_3_68_1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0031-6997(24)01414-5","volume":"51","author":"Masson J","year":"1999","unstructured":"Masson J , SagnC, HamonM, Mestikawy\u00a0SE: Neurotransmitter transporters in the central nervous system. Pharmacol. Rev.51, 439\u2013464 (1999).","journal-title":"Pharmacol. Rev."},{"key":"e_1_3_2_3_69_1","volume":"275","author":"Chen J","year":"1998","unstructured":"Chen J -X, Pan H, Rothman TP, Wade PR, Gershon MD: Guinea pig 5-HT transporter: cloning, expression, distribution, and function in intestinal sensory reception. Am. J. Physiol.275, G433\u2013G438, (1998).","journal-title":"Am. J. Physiol."},{"key":"e_1_3_2_3_70_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.16-07-02352.1996"},{"key":"e_1_3_2_3_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40365.x"},{"key":"e_1_3_2_3_72_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5292.1527"},{"key":"e_1_3_2_3_73_1","first-page":"15","volume-title":"J. Clin. Psychiatry","author":"de Leon J","year":"2005","unstructured":"de Leon J , SusceMT, PanRM, FairchildM, KochWH, WedlundPJ: The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.J. Clin. Psychiatry66(1), 15\u201327 (2005)."}],"container-title":["Pharmacogenomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/14622416.6.5.491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T02:02:11Z","timestamp":1736128931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/14622416.6.5.491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.2217\/14622416.6.5.491"],"URL":"https:\/\/doi.org\/10.2217\/14622416.6.5.491","relation":{},"ISSN":["1462-2416","1744-8042"],"issn-type":[{"value":"1462-2416","type":"print"},{"value":"1744-8042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}